---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-23-000126"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:36:42.417582+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Praxis posts Q2 net loss $34.3M, plans ulixacaltamide Phase 3 after FDA meeting

## Summary
- Q2 net loss $34.3M, cash $124.3M; cash runway into Q1 2025 from June offering net $63.4M.
- Ulixacaltamide: FDA EOP2 meeting confirms Phase 3 plan; two studies starting Q4 2023, mADL11 primary endpoint, 60 mg, 12 weeks.
- PRAX-628 Phase 1 EEG showed pharmacodynamic activity at all doses; Phase 2 PPR study topline H2 2023; focal epilepsy Phase 2 H1 2024.
- Net loss $34.3M in Q2 2023 vs $60.2M in Q2 2022; R&D expenses $25.6M down from $43.6M.
- R&D Portfolio Day on Oct 2, 2023 to detail Phase 3 program for ulixacaltamide and additional Essential1 data.

## SEC filing metadata
- accession: 0001689548-23-000126
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954823000126/0001689548-23-000126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954823000126/prax-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-23-000126
- JSON: https://secwatch.observer/filing/0001689548-23-000126.json
- Plain text: https://secwatch.observer/filing/0001689548-23-000126.txt

## Key facts
- Earnings Releases
  Praxis Precision Medicines, Inc. reported financial results for second quarter 2023.
  - Period: second quarter 2023
  - Result: reported results
  source text: Praxis Precision Medicines, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689548/000168954823000126/0001689548-23-000126-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.